The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a greater substantial los